Avion Pharmaceuticals, Llc

Wash affected area(s) with cleansing cloth once or twice daily, or as directed by your physician. Wet affected area(s) with water. Wet cloth with a little water and work into a full lather. Cleanse affected area(s) with cloth for 10-20 seconds, avoiding eyes. Rinse thoroughly and pat dry. Discard cloth. Do not flush.

Wash affected areas with Rosula™ Wash 1-2 times or as directed by a physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10 - 20 seconds, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off Rosula™ Wash sooner or using less often.

DOSAGE AND ADMINISTRATION: Adults, one (1) capsule daily, with or without food, or as prescribed by your healthcare provider. Do not administer to children under the age of 12.

There is currently no dosage information available for this product. We apologize for any inconvenience.

DOSAGE AND ADMINISTRATION: Before, during and/or after pregnancy, one softgel daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: One tablet daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: Before, during and/or after pregnancy, one softgel daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: Usual adult dose is one tablet taken once or twice a day or prescribed by a physician.

DOSAGE AND ADMINISTRATION: One tablet daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: Before, during and/or after pregnancy, one softgel daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: One capsule daily with or without food or as prescribed by your healthcare provider.

DOSAGE AND ADMINISTRATION: One softgel daily, or as directed by a physician.

DOSAGE AND ADMINISTRATION: One softgel daily, or as directed by a physician.

DOSAGE AND ADMINISTRATION: Before, during and/or after pregnancy, one softgel daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: One capsule daily with or without food or as prescribed by your healthcare provider.

* Daily Value (DV) not established. Supplement Facts Serving Size: 1 Softgel Amount per Serving: % Daily Value % Daily Value(Pregnant & Lactating Women) Vitamin C (as ascorbic acid) 60 mg 100% 100% Vitamin D3 (as cholecalciferol) 1000 IU 250% 250% Vitamin E (as dl-alpha tocopherol) 10 IU 33% 33% Vitamin B6 (as pyridoxine HCl) 26 mg 1300% 1040% Folate (as ((6S)-N5-methyltetrahydrofolic acid calcium salt (molar equivalent to 600 mcg of folic acid) and folic acid, USP 400 mcg) 1 mg 250% 125% Vitamin B12 (as cyanocobalamin) 13 mcg 217% 163% Biotin 280 mcg 93% 93% Calcium (as calcium carbonate) 80 mg 8% 6% Iron (as ferrous asparto glycinate) Sumalate® and (carbonyl iron) - Ferronyl® 18 mg 100% 100% Iodine (as potassium iodide) 150 mcg 100% 100% Magnesium (as magnesium oxide) 25 mg 6% 6% Docosahexaenoic Acid (DHA) 350 mg * * Blueberry extract (vaccinium spp.) 25 mg * *

Contains fish oil and soy.

DOSAGE AND ADMINISTRATION: Before, during and/or after pregnancy, one softgel daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: Remove the cleansing wipe from package and gently clean the affected area. Discard wipe after use. Please note that the cleansing wipe does not contain any active ingredients. Remove the child resistant cap and foil seal from the tube of Ana-Lex HC and screw on the provided applicator. Gently squeeze the tube until the applicator is full and a small amount of the cream comes out of the applicator opening. Insert the applicator tip gently into the anus and continue squeezing the body of the tube as it is moved around the areas of discomfort until the tube is empty. Do not completely insert the tube into the anus or insert deep into the rectum. Once the application is completed, the tube and applicator should be removed and discarded. Note that an adequate amount of Ana-Lex™ for an application to the anal and peri-anal area will be applied through the applicator tip by gently squeezing the tube during application. Ana-Lex™ should not be used in excess of recommendations or for prolonged use in the anal canal. If the condition does not respond to repeated courses of Ana-Lex™ or should worsen, discontinue use and seek the advice of your physician.

DOSAGE AND ADMINISTRATION: Before, during and/or after pregnancy, one tablet daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: Before, during and/or after pregnancy, one tablet daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: Before, during and/or after pregnancy, one softgel daily or as directed by a physician.

DOSAGE AND ADMINISTRATION: Before, during and/or after pregnancy, one softgel daily or as directed by a physician.

To achieve maximum contraceptive effectiveness, Levonorgestrel and Ethinyl Estradiol Tablets USP must be taken exactly as directed and at intervals not exceeding 24 hours. The dosage of Levonorgestrel and Ethinyl Estradiol Tablets is one orange tablet daily for 21 consecutive days, followed by one white inert tablet daily for 7 consecutive days, according to the prescribed schedule.

It is recommended that Levonorgestrel and Ethinyl Estradiol Tablets be taken at the same time each day.

During the First Cycle of Use

The possibility of ovulation and conception prior to initiation of medication should be considered. The patient should be instructed to begin taking Levonorgestrel and Ethinyl Estradiol Tablets on either the first Sunday after the onset of menstruation (Sunday Start) or on Day 1 of menstruation (Day 1 Start).

Sunday Start

The patient is instructed to begin taking Levonorgestrel and Ethinyl Estradiol Tablets on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, the first tablet (orange) is taken that day. One orange tablet should be taken daily for 21 consecutive days, followed by one white inert tablet daily for 7 consecutive days.

Withdrawal bleeding should usually occur within 3 days following discontinuation of orange tablets and may not have finished before the next pack is started. During the first cycle, contraceptive reliance should not be placed on Levonorgestrel and Ethinyl Estradiol Tablets until a orange tablet has been taken daily for 7 consecutive days, and a nonhormonal back-up method of birth control should be used during those 7 days.

Day 1 Start

During the first cycle of medication, the patient is instructed to begin taking Levonorgestrel and Ethinyl Estradiol Tablets during the first 24 hours of her period (day one of her menstrual cycle). One orange tablet should be taken daily for 21 consecutive days, followed by one white inert tablet daily for 7 consecutive days. Withdrawal bleeding should usually occur within 3 days following discontinuation of orange tablets and may not have finished before the next pack is started. If medication is begun on day one of the menstrual cycle, no back-up contraception is necessary. If Levonorgestrel and Ethinyl Estradiol Tablets is started later than day one of the first menstrual cycle or postpartum, contraceptive reliance should not be placed on Levonorgestrel and Ethinyl Estradiol Tablets until after the first 7 consecutive days of administration, and a nonhormonal back-up method of birth control should be used during those 7 days.

After the First Cycle of Use

The patient begins her next and all subsequent courses of tablets on the day after taking her last white tablet. She should follow the same dosing schedule: 21 days on orange tablets followed by 7 days on white tablets. If in any cycle the patient starts tablets later than the proper day, she should protect herself against pregnancy by using a nonhormonal back-up method of birth control until she has taken an orange tablet daily for 7 consecutive days.

Switching From Another Hormonal Method of Contraception

When the patient is switching from a 21 day regimen of tablets, she should wait 7 days after her last tablet before she starts Levonorgestrel and Ethinyl Estradiol Tablets She will probably experience withdrawal bleeding during that week. She should be sure that no more than 7 days pass after her previous 21 day regimen. When the patient is switching from a 28 day regimen of tablets, she should start her first pack of Levonorgestrel and Ethinyl Estradiol Tablets on the day after her last tablet. She should not wait any days between packs. The patient may switch any day from a progestin-only pill and should begin Levonorgestrel and Ethinyl Estradiol Tablets the next day. If switching from an implant or injection, the patient should start Levonorgestrel and Ethinyl Estradiol Tablets on the day of implant removal or, if using an injection, the day the next injection would be due. In switching from a progestin-only pill, injection, or implant, the patient should be advised to use a nonhormonal back-up method of birth control for the first 7 days of tablet-taking.

If Spotting or Breakthrough Bleeding Occurs

If spotting or breakthrough bleeding occur, the patient is instructed to continue on the same regimen. This type of bleeding is usually transient and without significance; however, if the bleeding is persistent or prolonged, the patient is advised to consult her physician.

Risk of Pregnancy if Tablets are Missed

While there is little likelihood of ovulation occurring if only one or two orange tablets are missed, the possibility of ovulation increases with each successive day that scheduled orange tablets are missed. Although the occurrence of pregnancy is unlikely if Levonorgestrel and Ethinyl Estradiol Tablets is taken according to directions, if withdrawal bleeding does not occur, the possibility of pregnancy must be considered. If the patient has not adhered to the prescribed schedule (missed one or more tablets or started taking them on a day later than she should have), the probability of pregnancy should be considered at the time of the first missed period and appropriate diagnostic measures taken. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out.

The risk of pregnancy increases with each active (orange) tablet missed. For additional patient instructions regarding missed tablets, see the WHAT TO DO IF YOU MISS PILLS in the DETAILED PATIENT LABELING below.

Use After Pregnancy, Abortion or Miscarriage

Levonorgestrel and Ethinyl Estradiol Tablets may be initiated no earlier than day 28 postpartum in the nonlactating mother or after a second trimester abortion due to the increased risk for thromboembolism (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS concerning thromboembolic disease). The patient should be advised to use a non-hormonal back-up method for the first 7 days of tablet taking.

Levonorgestrel and Ethinyl Estradiol Tablets may be initiated immediately after a first trimester abortion or miscarriage. If the patient starts Levonorgestrel and Ethinyl Estradiol Tablets immediately, back-up contraception is not needed.

Carefully consider the potential benefits and risks of DISALCID (Salsalate) TABLETS and other treatment options before deciding to use DISALCID (Salsalate) TABLETS. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

After observing the response to initial therapy with DISALCID (Salsalate) TABLETS, the dose and frequency should be adjusted to suit an individual patient's needs. Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder.

Adults: The usual dosage is 3000 mg daily, given in divided doses as follows:

1) two doses of two 750 mg tablets; 2) two doses of three 500 mg tablets; or 3) three doses of two 500 mg tablets. Some patients, e.g., the elderly, may require a lower dosage to achieve therapeutic blood concentrations and to avoid the more common side effects such as auditory.

Alleviation of symptoms is gradual, and full benefit may not be evident for 3 to 4 days, when plasma salicylate levels have achieved steady state. There is no evidence for development of tissue tolerance (tachyphylaxis), but salicylate therapy may induce increased activity of metabolizing liver enzymes, causing a greater rate of salicyluric acid production and excretion, with a resultant increase in dosage requirement for maintenance of therapeutic serum salicylate levels.

Children: Dosage recommendations and indications for salsalate use in children have not been established.